Beta Drugs Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 19 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.8K Cr
Beta Drugs plans to grow at a robust pace of 20-25% annually, as emphasized multiple times in the call. Beta Drugs aims to grow at a consistent pace of 20-25% annually, backed by a robust pipeline and strong execution (Page 15, Rahul Batra closing comments).
From Beta Drugs Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,328
Market Cap
₹2.8K Cr
P/E Ratio
62.0
How does Beta Drugs Ltd rank in Pharmaceuticals & Biotechnology?
Compare Beta Drugs Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Beta Drugs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹94 Cr, net profit ₹9 Cr.
Full financials →📊 Revenue & Sales Performance
- →Beta Drugs plans to grow at a robust pace of 20-25% annually, as emphasized multiple times in the call.
- →Export sales are expected to see significant growth in the second half of FY26, potentially crossing Rs.100 crores, up from Rs.43 crores in the first half.
- →The CDMO business grew 8% YoY and is expected to maintain steady contributions by adding new products and partners.
- →In the domestic market, new molecule launches and own branded products are expected to drive growth, including two NDDS products planned for next year.
- →The dermatology/cosmetic division aims for Rs.30-50 crores in sales over the next 3-5 years, focusing on scaling current SKUs before launching new ones.
- →In-licensing and biosimilars are strategic growth areas, with potential product launches in 3-4 years.
- →Overall, the company targets sustained top-line growth backed by product pipeline expansions and entry into new regulated markets.
📈 Profitability & Margins
- →Beta Drugs aims to grow at a consistent pace of 20-25% annually, backed by a robust pipeline and strong execution (Page 15, Rahul Batra closing comments).
- →EBITDA margins are expected to remain stable between 23% and 25% for FY26 (Page 8).
- →Exports, currently tender-driven with slower first-half performance, are expected to grow significantly in the second half, potentially crossing Rs.100 crores (Page 12).
- →Development of new products, including three drug filings and two new NDDS next year, will drive growth over the next 3-5 years (Page 5).
- →Growth will also be supported by expansion in derma/cosmetic business projected to reach Rs.30-50 crores per year in 3-5 years (Page 10).
- →Biosimilar entry planned within 3-4 years, potentially adding new revenue streams (Page 11).
- →Working capital and receivables expected to normalize with volume growth; no major impact anticipated on profitability (Pages 13-14).
🏗️ Capital Expenditure Plans
- →Beta Drugs acquired an oncology intermediate plant with a CAPEX of around Rs.9.45 crores; additional Rs.15-20 crores planned for building and machinery to operationalize it within 6-8 months.
- →Purchased land for an intermediate plant and a corporate R&D center; final payments pending due to registry processes.
- →Fixed asset additions amounting to approximately Rs.25 crores in H1FY26, including expenditure on buildings.
- →Cash reserves are being held for new product development, potential inorganic growth opportunities, and in-licensing biosimilars.
- →The company is planning biosimilar development with ongoing discussions and NDAs, aiming for product launches in 3-4 years.
- →Investment in capacity expansion at Adley formulation plant to support domestic sales and CDMO growth.
💰 Fundraising & Capital Structure
- →Currently, Beta Drugs Limited has no explicit mention of new fundraising plans through debt or equity in the call.
- →The company has maintained some cash reserves mainly for new product development, inorganic growth opportunities, and potential biosimilar in-licensing.
- →Existing borrowings, including convertible debentures, are expected to be converted by June next year, which will reduce leverage.
- →No specific new issuance of debt or equity was discussed during the call.
- →The management emphasized using cash reserves for CAPEX, including the oncology intermediate plant and R&D facilities, but no fundraising linked to these was mentioned.
📋 Order Book & Pipeline
- →The company had an order book that could not be processed fully by September, resulting in Rs.10-12 crores of orders to be dispatched in October and November (Page 11).
- →Exports are tender-driven, with most tenders awarded between October and December, leading to expected higher sales from January onwards (Pages 7 and 12).
- →In October alone, three major tenders were filed, with two more planned in different geographies soon (Page 12).
- →The company expects export revenues to cross Rs.100 crores in the second half of FY26, nearly doubling from Rs.43 crores in the first half (Page 12).
- →The order backlog and tender pipeline indicate strong growth momentum to meet the annual target growth of 20-25% (Pages 11 and 12).
Key Metrics
Frequently Asked Questions
What were Beta Drugs Ltd Q2 FY26 results?
Beta Drugs plans to grow at a robust pace of 20-25% annually, as emphasized multiple times in the call. Beta Drugs aims to grow at a consistent pace of 20-25% annually, backed by a robust pipeline and strong execution (Page 15, Rahul Batra closing comments).
What is Beta Drugs Ltd share price analysis?
Beta Drugs Ltd currently shows a neutral. The stock trades at a P/E of 62.0 with a market cap of ₹2,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Beta Drugs Ltd planning capital expenditure?
Beta Drugs acquired an oncology intermediate plant with a CAPEX of around Rs.9.45 crores; additional Rs.15-20 crores planned for building and machinery to operationalize it within 6-8 months.
Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.